Semaglutide dose-dependently reduced binge-like and dependence-induced alcohol drinking across two rodent species while enhancing GABA neurotransmission in brain regions controlling addiction, supporting clinical trials for alcohol use disorder.
Alcohol reduction across multiple models and both speciesSemaglutide reduced alcohol consumption in every model tested — binge drinking in mice, binge drinking in rats, and dependence-induced drinking in rats — across both sexes, providing robust preclinical support for clinical trials.
What the researchers found
Semaglutide demonstrated broad anti-alcohol effects across models and species:
- Dose-dependently reduced binge-like alcohol drinking in mice (drinking-in-the-dark model)
- Also reduced intake of other caloric/noncaloric solutions, suggesting a general reward-reducing effect
- Reduced binge-like and dependence-induced alcohol drinking in rats
- Effects observed in both male and female animals
Mechanistically, semaglutide increased spontaneous inhibitory postsynaptic current (sIPSC) frequency in central amygdala (CeA) and infralimbic cortex (ILC) neurons from alcohol-naive rats, indicating enhanced GABA release. However, this effect was absent in alcohol-dependent rats, suggesting chronic alcohol exposure may alter GLP-1 receptor-GABA interactions.
Why it matters
Alcohol use disorder affects approximately 283 million people worldwide and has limited effective pharmacotherapies. Semaglutide is already widely available and well-characterized for safety, meaning it could potentially be repurposed for AUD much faster than developing an entirely new drug. The NIH/NIDA-affiliated research team behind this study and the growing anecdotal evidence from semaglutide users add momentum to clinical trials already underway.
How the study worked
Multiple rodent models were used: a drinking-in-the-dark procedure for binge-like drinking in male and female mice, and both binge-like and dependence-induced drinking models in male and female rats. Electrophysiology experiments measured spontaneous inhibitory postsynaptic currents (sIPSCs) in central amygdala and infralimbic cortex neurons from both alcohol-naive and alcohol-dependent rats after acute semaglutide application.
What this study cannot tell us
All data is from rodent models, which don't fully replicate human drinking patterns or the complexity of alcohol use disorder. The GABA modulation effect was absent in alcohol-dependent rats, raising questions about efficacy in heavily dependent individuals. Semaglutide also reduced non-alcohol caloric intake, making it unclear whether the anti-alcohol effect is specific to alcohol reward or reflects a general reduction in consumption. Human clinical trial data is needed to confirm these findings.
How to read the evidence
This is a rigorous preclinical study published in JCI Insight by a leading NIH addiction research team. The use of multiple species, both sexes, multiple drinking models, and a combination of behavioral and electrophysiological methods provides strong mechanistic evidence, though clinical translation awaits human trial data.
When this study was published
Published in 2023, this study is recent and highly relevant given the surge of interest in GLP-1 drugs for addiction treatment. Several clinical trials of semaglutide for alcohol use disorder are now underway, building directly on this preclinical evidence.
The bigger picture
This study from George Koob's lab (former NIDA director) and Lorenzo Leggio's addiction research group provides foundational preclinical evidence for one of the most exciting emerging applications of GLP-1 drugs: treating addiction. The finding that semaglutide reduces not just alcohol but also other caloric/noncaloric rewards suggests it may broadly attenuate reward-seeking behavior through GLP-1 receptor signaling in brain addiction circuits. Clinical trials of GLP-1 drugs for AUD and other substance use disorders are now underway.
Questions still open
- Will the anti-alcohol effects of semaglutide translate to reduced drinking in human clinical trials for alcohol use disorder?
- Why does semaglutide fail to modulate GABA transmission in alcohol-dependent rats — does this predict reduced efficacy in severe AUD patients?
- Is the reduction in alcohol intake a specific anti-reward effect or simply a secondary consequence of semaglutide's appetite-suppressing properties?
Common questions
Why would a diabetes/weight loss drug reduce alcohol consumption?
Can I use semaglutide to help me drink less?
Read the original research
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.
JCI insight, 8(12)
Citation
Chuong, Vicky; Farokhnia, Mehdi; Khom, Sophia; Pince, Claire L; Elvig, Sophie K; Vlkolinsky, Roman; Marchette, Renata Cn; Koob, George F; Roberto, Marisa; Vendruscolo, Leandro F; Leggio, Lorenzo. (2023). The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.. JCI insight, 8(12). https://doi.org/10.1172/jci.insight.170671